Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.
Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.